Abstract Aim-Phase I study to evaluate intraventricular fibrinolytic treatment with recombinant tissue plasminogen activator (tPA) as a method of clearing blood from the cerebrospinal fluid, and thus preventing permanent hydrocephalus. Methods 
The past 15 years have seen extensive research in the aetiology and prophylaxis of intraventricular haemorrhage (IVH) in preterm infants.' Many neonatal centres have experienced a reduction in the incidence of IVH. Nevertheless, we lack safe and effective treatment for its most serious direct complication, posthaemorrhagic hydrocephalus (PHH). Early ventriculo-peritoneal shunting has a high rate of blockage, infection, and skin ulceration. 2 External ventricular drainage has a high rate of infection in most centres. Early treatment with repeated lumbar or ventricular punctures has not been shown to reduce the need for shunts, or to improve neurological outcome 3-5; and repeated tapping has a 7% risk of infection.' Drugs to reduce the production of cerebrospinal fluid have side effects and have not been shown to improve outcome. 67 Hill et al hypothesised that the initial phase of PHH was caused by multiple small blood clots which obstructed the arachnoid villi, the main sites of reabsorption of cerebrospinal fluid. 8 This being so, there should be a period of time during which PHH is potentially reversible if the blood clots can be cleared before chronic arachnoiditis in the basal cisterns renders the hydrocephalus permanent. 9 There is evidence of endogenous fibrinolytic activity in cerebrospinal fluid about 18 days after IVH, which continues for many weeks.'0 Posthaemorrhagic cerebrospinal fluid contains high concentrations of fibrin degradation products," and tissue plasminogen activator (tPA) is present in posthaemorrhagic cerebrospinal fluid. ' 2 Two animal models of PHH (dogs and cats) have shown that intraventricular urokinase " or intracisternal tPA,'4 starting within 24 hours of the injection of blood, can significantly reduce the risk of subsequent hydrocephalus. Recombinant human tPA has been quite widely used intrathecally as part of the management of subarachnoid haemorrhage after surgery for aneurysm."-"' Intraventricular tPA has been used with apparent success in adults with intraventricular haemorrhage, when combined with ventricular drainage. '9 21 Our first pilot study of intraventricular fibrinolytic treatment, in infants who were just beginning to develop PHH, involved the use of streptokinase. We chose streptokinase because Stewart had previously shown that it could safely be given in intraventricular mode to infants, because of its relatively low cost and because,22 at that time (1990), there was no published evidence that tPA could be given safely into the cerebrospinal fluid. The first nine infants showed encouraging results,2' but this was not sustained and of 13 infants treated, one died early and four became shunt dependent. purposes of obtaining pharmacokinetic information. Eight cerebrospinal fluid samples taken 24 hours after the injection of 1 mg tPA were analysed for tPA antigen. In one infant we were able to analyse seven daily ventricular cerebrospinal fluid samples obtained for clinical indications after a single intraventricular dose of 1 mg tPA. In two other infants (on three occasions) we were able to examine two sequential ventricular cerebrospinal fluid samples after 1 mg tPA. This allowed us to examine the clearance of exogenous tPA from the cerebrospinal fluid using the same ELISA technique.
This study was approved by the Norwegian Medicines Control Authority and the local Research Ethics Committees. Informed consent to tPA treatment was obtained from the parents of each infant.
Results Table 1 shows the characteristics of the 22 preterm infants who entered the study. Median birthweight was 1300 g (range 805-2500 g). Median gestation was 28.5 weeks (range [26] [27] [28] [29] [30] [31] [32] [33] . Using Papile's classification,29 14 had grade 3 IVH and eight had grade 4 IVH. Nineteen had had respiratory distress syndrome treated with mechanical ventilation and surfactant. Two had had confirmed septicaemia. Three had had persistent pulmonary hypertension. Three had had birth asphyxia. Median age at diagnosis of IVH was 2 days (range 0-6 days). The median age at which the infant reached treatment criteria was 12 days ( range 6-26 days). The median age at start of treatment was 15 days ( range 8-26 days). Two infants received one dose, nine received two doses, two received three doses, three received four doses and six received five doses. The median dose interval was two days and the range was one to seven days.
CLINICAL OUTCOME Figure 4 shows the lateral ventricles distended with diffuse echogenic blood which had not been present a few days before. Blood was aspirated from the ventricle to normalise intracranial pressure; 10 mg/kg tranexamic acid (Cyklokapron, Kabi Pharmacia) was immediately given intravenously to inhibit plasmin, and a blood transfusion was started. The infant stabilised within a few hours. She subsequently had a ventriculoperitoneal shunt operation, and had mild motor delay with increased tone on the right side 12 months after birth (fig 4) .
Systemic fibrinolysis
Plasma fibrinogen before tPA treatment was mean 2.28(SD 1.14) g/l. The lowest plasma fibrinogen concentrations during tPA treatment were 2.04 (1.90) g/l. In two infants (cases 7 and 19) the plasma fibrinogen fell from over 1.0 g/l to 0.5 g/l and 0.28 g/l, respectively, recovering after three and five days. In three other infants plasma fibrinogen fell transiently to 0.8, 0.9 and 0.98 g/l. There was no clinically evident systemic bleeding tendency in any infant. Fibrinolytic treatment has always been associated with concern about secondary haemorrhage and this complication occurred in one (4.5%) of the infants in our study. Fortunately, the infant recovered with prompt treatment. Nevertheless, such a complication is highly undesirable. The mechanism of secondary Whitelaw, Saliba, Fellman, Mowinckel, Acolet, Marlow Figure 2 Mid-coronal cerebral ultrasound scans (case 15). Scan 2A was taken before tPA treatment started. There is a large (white) clot in the right lateral ventricle and a small clot in the left lateral ventricle. Both lateral ventricles are dilated as is the third ventricle. Scan 2B is a corresponding scan 11 days after starting tPA treatment. There was virtually no reduction in the amount of intraventricular clot. Figure 3 Mid-coronal cerebral ultrasound scan (casel 6). Scan 3A was taken before the start of tPA. There is a large (white) clot in the right lateral ventricle as well as bilateral dilatation and a porencephalic cyst. Scan 3B was taken six days after starting tPA treatment. There is a moderate reduction in the amount of intraventricular clot. Scan 3C, taken 14 days after starting tPA, shows a further reduction in the amount of intraventricular blood clot. Scan 3D is a corresponding scan 25 days after tPA treatment was started. The intraventricular clot has completely disappeared, but the ventricular system is still dilated. 
